
zzso is a novel zzso zzso inhibitor with single agent activity in zzso zzso cell zzso and breast zzso The recommended Phase II dose of zzso administered as a single agent is 3 zzso every 3 zzso zzso also has a broad spectrum of zzso A Phase I study of both agents in combination therapy was zzso 

zzso patients had zzso solid tumors and a Cancer and zzso Group B performance status of 0 to zzso zzso of patients were treated with escalating doses of zzso as a 15-minute intravenous infusion immediately followed by 175 zzso of zzso administered over 3 zzso zzso toxicity was defined as World Health Organization Grade 4 zzso with fever, Grade 4 zzso requiring zzso zzso a zzso toxicity of Grade 3 or higher zzso zzso zzso and zzso or failure of zzso to recover to Grade 1 or lower within 21 days after causing a dose zzso 

A total of 33 patients enrolled in the zzso zzso was escalated in increments of zzso zzso from zzso zzso to the recommended Phase II dose of 3 zzso zzso toxicity first was observed at a zzso dose of 2 zzso At a dose of 3 zzso zzso zzso was observed in 2 of 12 zzso zzso was the other zzso zzso Two patients achieved a partial response (one patient with zzso of the head and neck and another with gallbladder zzso 

The authors conclude that zzso and zzso may be administered in combination at their respective single agent Phase II zzso Phase II testing of this combination is zzso 

